Skip to main content
PMC home page
Heart logoLink to Heart
. 1998 Dec;80(Suppl 2):S1–S29.

Joint British recommendations on prevention of coronary heart disease in clinical practice

PMCID: PMC1766497  PMID: 10193438

Full Text

The Full Text of this article is available as a PDF (489.2 KB).

Figure 1  .

Figure 1  

Figure 1  

Open in a new tab

Joint British Societies coronary risk prediction charts for men and women. The chart should not be used for predicting risk in patients with coronary or other major atherosclerotic disease, familial hypercholesterolaemia or those with renal dysfunction. (Copyright The University of Manchester)

Figure 2  .

Figure 2  

Open in a new tab

Absolute CHD risk and management of blood pressure in primary prevention of CHD and other atherosclerotic disease. CHD risk, non-fatal myocardial infarction and coronary death over 10 years.

Figure 3  .

Figure 3  

Open in a new tab

Absolute CHD risk and management of blood lipids in primary prevention of CHD and other atherosclerotic disease. CHD risk, non-fatal myocardial infarction and coronary death over 10 years.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberti K. G., Zimmet P. Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998 Jul;15(7):539–553. doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
  2. Amery A., Birkenhäger W., Brixko P., Bulpitt C., Clement D., Deruyttere M., De Schaepdryver A., Dollery C., Fagard R., Forette F. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985 Jun 15;1(8442):1349–1354. doi: 10.1016/s0140-6736(85)91783-0. [DOI] [PubMed] [Google Scholar]
  3. Anastos K., Charney P., Charon R. A., Cohen E., Jones C. Y., Marte C., Swiderski D. M., Wheat M. E., Williams S. Hypertension in women: what is really known? The Women's Caucus, Working Group on Women's Health of the Society of General Internal Medicine. Ann Intern Med. 1991 Aug 15;115(4):287–293. doi: 10.7326/0003-4819-115-4-287. [DOI] [PubMed] [Google Scholar]
  4. Anderson K. M., Wilson P. W., Odell P. M., Kannel W. B. An updated coronary risk profile. A statement for health professionals. Circulation. 1991 Jan;83(1):356–362. doi: 10.1161/01.cir.83.1.356. [DOI] [PubMed] [Google Scholar]
  5. Assmann G., Cullen P., Schulte H. The Münster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J. 1998 Feb;19 (Suppl A):A2–11. [PubMed] [Google Scholar]
  6. Austoker J., Sanders D., Fowler G. Smoking and cancer: smoking cessation. BMJ. 1994 Jun 4;308(6942):1478–1482. doi: 10.1136/bmj.308.6942.1478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Barrett-Connor E., Wingard D. L., Criqui M. H., Suarez L. Is borderline fasting hyperglycemia a risk factor for cardiovascular death? J Chronic Dis. 1984;37(9-10):773–779. doi: 10.1016/0021-9681(84)90046-8. [DOI] [PubMed] [Google Scholar]
  8. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S) Lancet. 1995 May 20;345(8960):1274–1275. [PubMed] [Google Scholar]
  9. Berlin J. A., Colditz G. A. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol. 1990 Oct;132(4):612–628. doi: 10.1093/oxfordjournals.aje.a115704. [DOI] [PubMed] [Google Scholar]
  10. Betteridge D. J., Dodson P. M., Durrington P. N., Hughes E. A., Laker M. F., Nicholls D. P., Rees J. A., Seymour C. A., Thompson G. R., Winder A. F. Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J. 1993 May;69(811):359–369. doi: 10.1136/pgmj.69.811.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Bhatnagar D., Anand I. S., Durrington P. N., Patel D. J., Wander G. S., Mackness M. I., Creed F., Tomenson B., Chandrashekhar Y., Winterbotham M. Coronary risk factors in people from the Indian subcontinent living in west London and their siblings in India. Lancet. 1995 Feb 18;345(8947):405–409. doi: 10.1016/s0140-6736(95)90398-4. [DOI] [PubMed] [Google Scholar]
  12. Blair S. N., Kohl H. W., 3rd, Paffenbarger R. S., Jr, Clark D. G., Cooper K. H., Gibbons L. W. Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA. 1989 Nov 3;262(17):2395–2401. doi: 10.1001/jama.262.17.2395. [DOI] [PubMed] [Google Scholar]
  13. Blankenhorn D. H., Nessim S. A., Johnson R. L., Sanmarco M. E., Azen S. P., Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987 Jun 19;257(23):3233–3240. [PubMed] [Google Scholar]
  14. Bulpitt C. J., Beevers D. G., Butler A., Coles E. C., Hunt D., Munro-Faure A. D., Newson R. B., O'Riordan P. W., Petrie J. C., Rajagopalan B. The survival of treated hypertensive patients and their causes of death: a report from the DHSS hypertensive care computing project (DHCCP). J Hypertens. 1986 Feb;4(1):93–99. doi: 10.1097/00004872-198602000-00015. [DOI] [PubMed] [Google Scholar]
  15. Burr M. L., Fehily A. M., Gilbert J. F., Rogers S., Holliday R. M., Sweetnam P. M., Elwood P. C., Deadman N. M. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989 Sep 30;2(8666):757–761. doi: 10.1016/s0140-6736(89)90828-3. [DOI] [PubMed] [Google Scholar]
  16. Carlsen J. E., Køber L., Torp-Pedersen C., Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ. 1990 Apr 14;300(6730):975–978. doi: 10.1136/bmj.300.6730.975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Carter A. B. Hypotensive therapy in stroke survivors. Lancet. 1970 Mar 7;1(7645):485–489. doi: 10.1016/s0140-6736(70)91577-1. [DOI] [PubMed] [Google Scholar]
  18. Casper M., Wing S., Strogatz D. Variation in the magnitude of black-white differences in stroke mortality by community occupational structure. J Epidemiol Community Health. 1991 Dec;45(4):302–306. doi: 10.1136/jech.45.4.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Cohn J. N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., Smith R., Dunkman W. B., Loeb H., Wong M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):303–310. doi: 10.1056/NEJM199108013250502. [DOI] [PubMed] [Google Scholar]
  20. Colhoun H. M., Dong W., Poulter N. R. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens. 1998 Jun;16(6):747–752. doi: 10.1097/00004872-199816060-00005. [DOI] [PubMed] [Google Scholar]
  21. Collins R., MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull. 1994 Apr;50(2):272–298. doi: 10.1093/oxfordjournals.bmb.a072892. [DOI] [PubMed] [Google Scholar]
  22. Cooper M. E. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet. 1998 Jul 18;352(9123):213–219. doi: 10.1016/S0140-6736(98)01346-4. [DOI] [PubMed] [Google Scholar]
  23. Crane M. G., Harris J. J., Winsor W., 3rd Hypertension, oral contraceptive agents, and conjugated estrogens. Ann Intern Med. 1971 Jan;74(1):13–21. doi: 10.7326/0003-4819-74-1-13. [DOI] [PubMed] [Google Scholar]
  24. Cruickshank J. K., Cooper J., Burnett M., MacDuff J., Drubra U. Ethnic differences in fasting plasma C-peptide and insulin in relation to glucose tolerance and blood pressure. Lancet. 1991 Oct 5;338(8771):842–847. doi: 10.1016/0140-6736(91)91501-k. [DOI] [PubMed] [Google Scholar]
  25. Cruickshank J. M., Thorp J. M., Zacharias F. J. Benefits and potential harm of lowering high blood pressure. Lancet. 1987 Mar 14;1(8533):581–584. doi: 10.1016/s0140-6736(87)90231-5. [DOI] [PubMed] [Google Scholar]
  26. Curb J. D., Pressel S. L., Cutler J. A., Savage P. J., Applegate W. B., Black H., Camel G., Davis B. R., Frost P. H., Gonzalez N. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996 Dec 18;276(23):1886–1892. [PubMed] [Google Scholar]
  27. Curtis J. J., Luke R. G., Whelchel J. D., Diethelm A. G., Jones P., Dustan H. P. Inhibition of angiotensin-converting enzyme in renal-transplant recipients with hypertension. N Engl J Med. 1983 Feb 17;308(7):377–381. doi: 10.1056/NEJM198302173080707. [DOI] [PubMed] [Google Scholar]
  28. D'Agostino R. B., Belanger A. J., Kannel W. B., Cruickshank J. M. Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study. BMJ. 1991 Aug 17;303(6799):385–389. doi: 10.1136/bmj.303.6799.385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Dacosta A., Guy J. M., Tardy B., Gonthier R., Denis L., Lamaud M., Cerisier A., Verneyre H. Myocardial infarction and nicotine patch: a contributing or causative factor? Eur Heart J. 1993 Dec;14(12):1709–1711. doi: 10.1093/eurheartj/14.12.1709. [DOI] [PubMed] [Google Scholar]
  30. Dahlöf B., Lindholm L. H., Hansson L., Scherstén B., Ekbom T., Wester P. O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) Lancet. 1991 Nov 23;338(8778):1281–1285. doi: 10.1016/0140-6736(91)92589-t. [DOI] [PubMed] [Google Scholar]
  31. Daly L. E., Mulcahy R., Graham I. M., Hickey N. Long term effect on mortality of stopping smoking after unstable angina and myocardial infarction. Br Med J (Clin Res Ed) 1983 Jul 30;287(6388):324–326. doi: 10.1136/bmj.287.6388.324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Davey Smith G., Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ. 1992 Feb 15;304(6824):431–434. doi: 10.1136/bmj.304.6824.431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Dean J. D., Durrington P. N. Treatment of dyslipoproteinaemia in diabetes mellitus. Diabet Med. 1996 Apr;13(4):297–312. doi: 10.1002/(SICI)1096-9136(199604)13:4<297::AID-DIA82>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  34. Degoulet P., Legrain M., Réach I., Aimé F., Devriés C., Rojas P., Jacobs C. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron. 1982;31(2):103–110. doi: 10.1159/000182627. [DOI] [PubMed] [Google Scholar]
  35. Dobson A. J., Alexander H. M., Heller R. F., Lloyd D. M. How soon after quitting smoking does risk of heart attack decline? J Clin Epidemiol. 1991;44(11):1247–1253. doi: 10.1016/0895-4356(91)90157-5. [DOI] [PubMed] [Google Scholar]
  36. Downs J. R., Clearfield M., Weis S., Whitney E., Shapiro D. R., Beere P. A., Langendorfer A., Stein E. A., Kruyer W., Gotto A. M., Jr Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998 May 27;279(20):1615–1622. doi: 10.1001/jama.279.20.1615. [DOI] [PubMed] [Google Scholar]
  37. Durrington P. N. Serum high density lipoprotein cholesterol in diabetes mellitus: an analysis of factors which influence its concentration. Clin Chim Acta. 1980 May 21;104(1):11–23. doi: 10.1016/0009-8981(80)90130-8. [DOI] [PubMed] [Google Scholar]
  38. Durrington P. Statins and fibrates in the management of diabetic dyslipidemia. Diabet Med. 1997 Jul;14(7):513–516. doi: 10.1002/(SICI)1096-9136(199707)14:7<513::AID-DIA427>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
  39. Ericsson C. G., Hamsten A., Nilsson J., Grip L., Svane B., de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996 Mar 30;347(9005):849–853. doi: 10.1016/s0140-6736(96)91343-4. [DOI] [PubMed] [Google Scholar]
  40. Farrer M., Fulcher G., Albers C. J., Neil H. A., Adams P. C., Alberti K. G. Patients undergoing coronary artery bypass graft surgery are at high risk of impaired glucose tolerance and diabetes mellitus during the first postoperative year. Metabolism. 1995 Aug;44(8):1016–1027. doi: 10.1016/0026-0495(95)90099-3. [DOI] [PubMed] [Google Scholar]
  41. Feher M. D., Foxton J., Banks D., Lant A. F., Wray R. Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease. Br Heart J. 1995 Jul;74(1):14–17. doi: 10.1136/hrt.74.1.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Fonarow G. C., Chelimsky-Fallick C., Stevenson L. W., Luu M., Hamilton M. A., Moriguchi J. D., Tillisch J. H., Walden J. A., Albanese E. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol. 1992 Mar 15;19(4):842–850. doi: 10.1016/0735-1097(92)90529-v. [DOI] [PubMed] [Google Scholar]
  43. Frick M. H., Elo O., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P., Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237–1245. doi: 10.1056/NEJM198711123172001. [DOI] [PubMed] [Google Scholar]
  44. Fuller J. H., Shipley M. J., Rose G., Jarrett R. J., Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet. 1980 Jun 28;1(8183):1373–1376. doi: 10.1016/s0140-6736(80)92651-3. [DOI] [PubMed] [Google Scholar]
  45. Gall M. A., Hougaard P., Borch-Johnsen K., Parving H. H. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997 Mar 15;314(7083):783–788. doi: 10.1136/bmj.314.7083.783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Garrison R. J., Castelli W. P., Feinleib M., Kannel W. B., Havlik R. J., Padgett S. J., McNamara P. M. The association of total cholesterol, triglycerides and plasma lipoprotein cholesterol levels in first degree relatives and spouse pairs. Am J Epidemiol. 1979 Sep;110(3):313–321. doi: 10.1093/oxfordjournals.aje.a112816. [DOI] [PubMed] [Google Scholar]
  47. Gersh B. J., Rihal C. S., Rooke T. W., Ballard D. J. Evaluation and management of patients with both peripheral vascular and coronary artery disease. J Am Coll Cardiol. 1991 Jul;18(1):203–214. doi: 10.1016/s0735-1097(10)80241-4. [DOI] [PubMed] [Google Scholar]
  48. Giatras I., Lau J., Levey A. S. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med. 1997 Sep 1;127(5):337–345. doi: 10.7326/0003-4819-127-5-199709010-00001. [DOI] [PubMed] [Google Scholar]
  49. Gibson R. S., Boden W. E., Theroux P., Strauss H. D., Pratt C. M., Gheorghiade M., Capone R. J., Crawford M. H., Schlant R. C., Kleiger R. E. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N Engl J Med. 1986 Aug 14;315(7):423–429. doi: 10.1056/NEJM198608143150704. [DOI] [PubMed] [Google Scholar]
  50. Goldstein J. L., Brown M. S. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci U S A. 1973 Oct;70(10):2804–2808. doi: 10.1073/pnas.70.10.2804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Gould A. L., Rossouw J. E., Santanello N. C., Heyse J. F., Furberg C. D. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation. 1995 Apr 15;91(8):2274–2282. doi: 10.1161/01.cir.91.8.2274. [DOI] [PubMed] [Google Scholar]
  52. Gross V., Luft F. C. Nisoldipine and pressure-natriuresis curves in transgenic (mRen2)27 rats. J Hypertens. 1996 Apr;14(4):529–535. [PubMed] [Google Scholar]
  53. Gueyffier F., Boutitie F., Boissel J. P., Pocock S., Coope J., Cutler J., Ekbom T., Fagard R., Friedman L., Perry M. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med. 1997 May 15;126(10):761–767. doi: 10.7326/0003-4819-126-10-199705150-00002. [DOI] [PubMed] [Google Scholar]
  54. Haffner S. M., Lehto S., Rönnemaa T., Pyörälä K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998 Jul 23;339(4):229–234. doi: 10.1056/NEJM199807233390404. [DOI] [PubMed] [Google Scholar]
  55. Haffner S. M., Stern M. P., Hazuda H. P., Mitchell B. D., Patterson J. K. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990 Jun 6;263(21):2893–2898. doi: 10.1001/jama.263.21.2893. [DOI] [PubMed] [Google Scholar]
  56. Hansson L., Zanchetti A., Carruthers S. G., Dahlöf B., Elmfeldt D., Julius S., Ménard J., Rahn K. H., Wedel H., Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998 Jun 13;351(9118):1755–1762. doi: 10.1016/s0140-6736(98)04311-6. [DOI] [PubMed] [Google Scholar]
  57. Heady J. A., Morris J. N., Oliver M. F. WHO clofibrate/cholesterol trial: clarifications. Lancet. 1992 Dec 5;340(8832):1405–1406. doi: 10.1016/0140-6736(92)92588-7. [DOI] [PubMed] [Google Scholar]
  58. Hemminki E., McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ. 1997 Jul 19;315(7101):149–153. doi: 10.1136/bmj.315.7101.149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation. 1990 Dec;82(6):1916–1924. doi: 10.1161/01.cir.82.6.1916. [DOI] [PubMed] [Google Scholar]
  60. Horgan J., Bethell H., Carson P., Davidson C., Julian D., Mayou R. A., Nagle R. Working party report on cardiac rehabilitation. Br Heart J. 1992 May;67(5):412–418. doi: 10.1136/hrt.67.5.412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Jackson R., Barham P., Bills J., Birch T., McLennan L., MacMahon S., Maling T. Management of raised blood pressure in New Zealand: a discussion document. BMJ. 1993 Jul 10;307(6896):107–110. doi: 10.1136/bmj.307.6896.107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Johnston C. I., Cooper M. E., Nicholls G. M. Meeting report of the International Society of Hypertension Conference on Hypertension and Diabetes. J Hypertens. 1992 Apr;10(4):393–397. doi: 10.1097/00004872-199204000-00012. [DOI] [PubMed] [Google Scholar]
  63. Joseph A. M., Norman S. M., Ferry L. H., Prochazka A. V., Westman E. C., Steele B. G., Sherman S. E., Cleveland M., Antonuccio D. O., Antonnucio D. O. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996 Dec 12;335(24):1792–1798. doi: 10.1056/NEJM199612123352402. [DOI] [PubMed] [Google Scholar]
  64. Kane J. P., Malloy M. J., Ports T. A., Phillips N. R., Diehl J. C., Havel R. J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990 Dec 19;264(23):3007–3012. [PubMed] [Google Scholar]
  65. Kannel W. B., Dawber T. R., McGee D. L. Perspectives on systolic hypertension. The Framingham study. Circulation. 1980 Jun;61(6):1179–1182. doi: 10.1161/01.cir.61.6.1179. [DOI] [PubMed] [Google Scholar]
  66. Kawachi I., Colditz G. A., Stampfer M. J., Willett W. C., Manson J. E., Rosner B., Speizer F. E., Hennekens C. H. Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. Arch Intern Med. 1994 Jan 24;154(2):169–175. [PubMed] [Google Scholar]
  67. Klahr S., Levey A. S., Beck G. J., Caggiula A. W., Hunsicker L., Kusek J. W., Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994 Mar 31;330(13):877–884. doi: 10.1056/NEJM199403313301301. [DOI] [PubMed] [Google Scholar]
  68. Klatsky A. L., Armstrong M. A., Friedman G. D. Racial differences in cerebrovascular disease hospitalizations. Stroke. 1991 Mar;22(3):299–304. doi: 10.1161/01.str.22.3.299. [DOI] [PubMed] [Google Scholar]
  69. Klatsky A. L., Friedman G. D., Siegelaub A. B., Gérard M. J. Alcohol consumption and blood pressure Kaiser-Permanente Multiphasic Health Examination data. N Engl J Med. 1977 May 26;296(21):1194–1200. doi: 10.1056/NEJM197705262962103. [DOI] [PubMed] [Google Scholar]
  70. Koskinen P., Mänttäri M., Manninen V., Huttunen J. K., Heinonen O. P., Frick M. H. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992 Jul;15(7):820–825. doi: 10.2337/diacare.15.7.820. [DOI] [PubMed] [Google Scholar]
  71. Lakka T. A., Venäläinen J. M., Rauramaa R., Salonen R., Tuomilehto J., Salonen J. T. Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction. N Engl J Med. 1994 Jun 2;330(22):1549–1554. doi: 10.1056/NEJM199406023302201. [DOI] [PubMed] [Google Scholar]
  72. Langford H. G., Stamler J., Wassertheil-Smoller S., Prineas R. J. All-cause mortality in the Hypertension Detection and Follow-up Program: findings for the whole cohort and for persons with less severe hypertension, with and without other traits related to risk of mortality. Prog Cardiovasc Dis. 1986 Nov-Dec;29(3 Suppl 1):29–54. doi: 10.1016/0033-0620(86)90033-2. [DOI] [PubMed] [Google Scholar]
  73. Law M. R., Frost C. D., Wald N. J. By how much does dietary salt reduction lower blood pressure? I--Analysis of observational data among populations. BMJ. 1991 Apr 6;302(6780):811–815. doi: 10.1136/bmj.302.6780.811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Law M. R., Frost C. D., Wald N. J. By how much does dietary salt reduction lower blood pressure? III--Analysis of data from trials of salt reduction. BMJ. 1991 Apr 6;302(6780):819–824. doi: 10.1136/bmj.302.6780.819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Law M. R., Thompson S. G., Wald N. J. Assessing possible hazards of reducing serum cholesterol. BMJ. 1994 Feb 5;308(6925):373–379. doi: 10.1136/bmj.308.6925.373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Law M. R., Wald N. J., Thompson S. G. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994 Feb 5;308(6925):367–372. doi: 10.1136/bmj.308.6925.367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Law M. R., Wald N. J., Wu T., Hackshaw A., Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ. 1994 Feb 5;308(6925):363–366. doi: 10.1136/bmj.308.6925.363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Law M., Tang J. L. An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med. 1995 Oct 9;155(18):1933–1941. [PubMed] [Google Scholar]
  79. Laws A., Jeppesen J. L., Maheux P. C., Schaaf P., Chen Y. D., Reaven G. M. Resistance to insulin-stimulated glucose uptake and dyslipidemia in Asian Indians. Arterioscler Thromb. 1994 Jun;14(6):917–922. doi: 10.1161/01.atv.14.6.917. [DOI] [PubMed] [Google Scholar]
  80. Lazarus J. M., Bourgoignie J. J., Buckalew V. M., Greene T., Levey A. S., Milas N. C., Paranandi L., Peterson J. C., Porush J. G., Rauch S. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension. 1997 Feb;29(2):641–650. doi: 10.1161/01.hyp.29.2.641. [DOI] [PubMed] [Google Scholar]
  81. Levens N. R., Ksander G. M., Zimmerman M. B., Mullane K. M. Thromboxane synthase inhibition enhances action of converting enzyme inhibitors. Hypertension. 1989 Jan;13(1):51–62. doi: 10.1161/01.hyp.13.1.51. [DOI] [PubMed] [Google Scholar]
  82. Lewis E. J., Hunsicker L. G., Bain R. P., Rohde R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993 Nov 11;329(20):1456–1462. doi: 10.1056/NEJM199311113292004. [DOI] [PubMed] [Google Scholar]
  83. Linjer E., Hansson L. Underestimation of the true benefits of antihypertensive treatment: an assessment of some important sources of error. J Hypertens. 1997 Mar;15(3):221–225. doi: 10.1097/00004872-199715030-00002. [DOI] [PubMed] [Google Scholar]
  84. MBewu A. D., Durrington P. N., Bulleid S., Mackness M. I. The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein(a), apolipoproteins A1 and B, lipids and C-reactive protein. Atherosclerosis. 1993 Oct;103(1):65–71. doi: 10.1016/0021-9150(93)90040-2. [DOI] [PubMed] [Google Scholar]
  85. MacMahon S., Peto R., Cutler J., Collins R., Sorlie P., Neaton J., Abbott R., Godwin J., Dyer A., Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990 Mar 31;335(8692):765–774. doi: 10.1016/0140-6736(90)90878-9. [DOI] [PubMed] [Google Scholar]
  86. MacMahon S., Peto R., Cutler J., Collins R., Sorlie P., Neaton J., Abbott R., Godwin J., Dyer A., Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990 Mar 31;335(8692):765–774. doi: 10.1016/0140-6736(90)90878-9. [DOI] [PubMed] [Google Scholar]
  87. Malmberg K., Rydén L., Efendic S., Herlitz J., Nicol P., Waldenström A., Wedel H., Welin L. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995 Jul;26(1):57–65. doi: 10.1016/0735-1097(95)00126-k. [DOI] [PubMed] [Google Scholar]
  88. Mancini G. B. Angiographic trials of lipid-lowering therapy: an update. Curr Opin Lipidol. 1995 Dec;6(6):379–385. doi: 10.1097/00041433-199512000-00009. [DOI] [PubMed] [Google Scholar]
  89. Mann J. I., Crooke M., Fear H., Hay D. R., Jackson R. T., Neutze J. M., White H. D. Guidelines for detection and management of dyslipidaemia. Scientific Committee of the National Heart Foundation of New Zealand. N Z Med J. 1993 Apr 14;106(953):133–141. [PubMed] [Google Scholar]
  90. Manson J. E., Gaziano J. M., Jonas M. A., Hennekens C. H. Antioxidants and cardiovascular disease: a review. J Am Coll Nutr. 1993 Aug;12(4):426–432. doi: 10.1080/07315724.1993.10718332. [DOI] [PubMed] [Google Scholar]
  91. Margetts B. M., Beilin L. J., Vandongen R., Armstrong B. K. Vegetarian diet in mild hypertension: a randomised controlled trial. Br Med J (Clin Res Ed) 1986 Dec 6;293(6560):1468–1471. doi: 10.1136/bmj.293.6560.1468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Marmot M. G., Elliott P., Shipley M. J., Dyer A. R., Ueshima H., Beevers D. G., Stamler R., Kesteloot H., Rose G., Stamler J. Alcohol and blood pressure: the INTERSALT study. BMJ. 1994 May 14;308(6939):1263–1267. doi: 10.1136/bmj.308.6939.1263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Maschio G., Alberti D., Janin G., Locatelli F., Mann J. F., Motolese M., Ponticelli C., Ritz E., Zucchelli P. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996 Apr 11;334(15):939–945. doi: 10.1056/NEJM199604113341502. [DOI] [PubMed] [Google Scholar]
  94. Materson B. J., Reda D. J., Cushman W. C., Massie B. M., Freis E. D., Kochar M. S., Hamburger R. J., Fye C., Lakshman R., Gottdiener J. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993 Apr 1;328(13):914–921. doi: 10.1056/NEJM199304013281303. [DOI] [PubMed] [Google Scholar]
  95. McKeigue P. M., Marmot M. G., Syndercombe Court Y. D., Cottier D. E., Rahman S., Riemersma R. A. Diabetes, hyperinsulinaemia, and coronary risk factors in Bangladeshis in east London. Br Heart J. 1988 Nov;60(5):390–396. doi: 10.1136/hrt.60.5.390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. McKeigue P. M., Miller G. J., Marmot M. G. Coronary heart disease in south Asians overseas: a review. J Clin Epidemiol. 1989;42(7):597–609. doi: 10.1016/0895-4356(89)90002-4. [DOI] [PubMed] [Google Scholar]
  97. McKeigue P. M., Pierpoint T., Ferrie J. E., Marmot M. G. Relationship of glucose intolerance and hyperinsulinaemia to body fat pattern in south Asians and Europeans. Diabetologia. 1992 Aug;35(8):785–791. doi: 10.1007/BF00429101. [DOI] [PubMed] [Google Scholar]
  98. Mogensen C. E., Keane W. F., Bennett P. H., Jerums G., Parving H. H., Passa P., Steffes M. W., Striker G. E., Viberti G. C. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995 Oct 21;346(8982):1080–1084. doi: 10.1016/s0140-6736(95)91747-0. [DOI] [PubMed] [Google Scholar]
  99. Morris J. N., Clayton D. G., Everitt M. G., Semmence A. M., Burgess E. H. Exercise in leisure time: coronary attack and death rates. Br Heart J. 1990 Jun;63(6):325–334. doi: 10.1136/hrt.63.6.325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Moss A. J., Oakes D., Rubison M., McDermott M., Carleen E., Eberly S., Brown M. Effects of diltiazem on long-term outcome after acute myocardial infarction in patients with and without a history of systemic hypertension. The Multicenter Diltiazem Postinfarction Trial Research Group. Am J Cardiol. 1991 Aug 15;68(5):429–433. doi: 10.1016/0002-9149(91)90773-e. [DOI] [PubMed] [Google Scholar]
  101. Myers M. G., Carruthers S. G., Leenen F. H., Haynes R. B. Recommendations from the Canadian Hypertension Society Consensus Conference on the Pharmacologic Treatment of Hypertension. CMAJ. 1989 May 15;140(10):1141–1146. [PMC free article] [PubMed] [Google Scholar]
  102. Nabulsi A. A., Folsom A. R., White A., Patsch W., Heiss G., Wu K. K., Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med. 1993 Apr 15;328(15):1069–1075. doi: 10.1056/NEJM199304153281501. [DOI] [PubMed] [Google Scholar]
  103. Neil H. A., Roe L., Godlee R. J., Moore J. W., Clark G. M., Brown J., Thorogood M., Stratton I. M., Lancaster T., Mant D. Randomised trial of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins, and antioxidants. BMJ. 1995 Mar 4;310(6979):569–573. doi: 10.1136/bmj.310.6979.569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. O'Connor G. T., Buring J. E., Yusuf S., Goldhaber S. Z., Olmstead E. M., Paffenbarger R. S., Jr, Hennekens C. H. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation. 1989 Aug;80(2):234–244. doi: 10.1161/01.cir.80.2.234. [DOI] [PubMed] [Google Scholar]
  105. Oldridge N. B., Guyatt G. H., Fischer M. E., Rimm A. A. Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. JAMA. 1988 Aug 19;260(7):945–950. [PubMed] [Google Scholar]
  106. Paffenbarger R. S., Jr, Hyde R. T., Wing A. L., Lee I. M., Jung D. L., Kampert J. B. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N Engl J Med. 1993 Feb 25;328(8):538–545. doi: 10.1056/NEJM199302253280804. [DOI] [PubMed] [Google Scholar]
  107. Parving H. H. Initiation and progression of diabetic nephropathy. N Engl J Med. 1996 Nov 28;335(22):1682–1683. doi: 10.1056/NEJM199611283352212. [DOI] [PubMed] [Google Scholar]
  108. Pekkanen J., Linn S., Heiss G., Suchindran C. M., Leon A., Rifkind B. M., Tyroler H. A. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990 Jun 14;322(24):1700–1707. doi: 10.1056/NEJM199006143222403. [DOI] [PubMed] [Google Scholar]
  109. Petrie J. C., O'Brien E. T., Littler W. A., de Swiet M. Recommendations on blood pressure measurement. Br Med J (Clin Res Ed) 1986 Sep 6;293(6547):611–615. doi: 10.1136/bmj.293.6547.611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Pfeffer M. A., Braunwald E., Moyé L. A., Basta L., Brown E. J., Jr, Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. doi: 10.1056/NEJM199209033271001. [DOI] [PubMed] [Google Scholar]
  111. Pickering T. G. Can ambulatory blood pressure monitoring improve the diagnosis of mild hypertension? J Hypertens Suppl. 1990 Dec;8(6):S43–S47. [PubMed] [Google Scholar]
  112. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J. 1998 Oct;19(10):1434–1503. doi: 10.1053/euhj.1998.1243. [DOI] [PubMed] [Google Scholar]
  113. Pyke S. D., Wood D. A., Kinmonth A. L., Thompson S. G. Change in coronary risk and coronary risk factor levels in couples following lifestyle intervention. The British Family Heart Study. Arch Fam Med. 1997 Jul-Aug;6(4):354–360. doi: 10.1001/archfami.6.4.354. [DOI] [PubMed] [Google Scholar]
  114. Pyorälä K., Pedersen T. R., Kjekshus J., Faergeman O., Olsson A. G., Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care. 1997 Apr;20(4):614–620. doi: 10.2337/diacare.20.4.614. [DOI] [PubMed] [Google Scholar]
  115. Pyörälä K., Laakso M., Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987 Apr;3(2):463–524. doi: 10.1002/dmr.5610030206. [DOI] [PubMed] [Google Scholar]
  116. Ramsay L. E., Yeo W. W., Jackson P. R. Dietary reduction of serum cholesterol concentration: time to think again. BMJ. 1991 Oct 19;303(6808):953–957. doi: 10.1136/bmj.303.6808.953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  117. Rosenberg L., Palmer J. R., Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med. 1990 Jan 25;322(4):213–217. doi: 10.1056/NEJM199001253220401. [DOI] [PubMed] [Google Scholar]
  118. Rosenberg S. A. Combined modality therapy of cancer. What is it and when does it work? N Engl J Med. 1985 Jun 6;312(23):1512–1514. doi: 10.1056/NEJM198506063122309. [DOI] [PubMed] [Google Scholar]
  119. Rouse I. L., Beilin L. J., Armstrong B. K., Vandongen R. Blood-pressure-lowering effect of a vegetarian diet: controlled trial in normotensive subjects. Lancet. 1983 Jan 1;1(8314-5):5–10. doi: 10.1016/s0140-6736(83)91557-x. [DOI] [PubMed] [Google Scholar]
  120. Sackett D. L., Anderson G. D., Milner R., Feinleib M., Kannel W. B. Concordance for coronary risk factors among spouses. Circulation. 1975 Oct;52(4):589–595. doi: 10.1161/01.cir.52.4.589. [DOI] [PubMed] [Google Scholar]
  121. Sacks F. M., Pfeffer M. A., Moye L. A., Rouleau J. L., Rutherford J. D., Cole T. G., Brown L., Warnica J. W., Arnold J. M., Wun C. C. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 Oct 3;335(14):1001–1009. doi: 10.1056/NEJM199610033351401. [DOI] [PubMed] [Google Scholar]
  122. Sevak L., McKeigue P. M., Marmot M. G. Relationship of hyperinsulinemia to dietary intake in south Asian and European men. Am J Clin Nutr. 1994 May;59(5):1069–1074. doi: 10.1093/ajcn/59.5.1069. [DOI] [PubMed] [Google Scholar]
  123. Sever P., Beevers G., Bulpitt C., Lever A., Ramsay L., Reid J., Swales J. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ. 1993 Apr 10;306(6883):983–987. doi: 10.1136/bmj.306.6883.983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  124. Shaukat N., Ashraf S. S., Mackness M. I., Mbewu A. D., Bhatnagar D., Durrington P. N. A prospective study of serum lipoproteins after coronary artery bypass surgery. QJM. 1994 Sep;87(9):539–545. [PubMed] [Google Scholar]
  125. Shelgikar K. M., Hockaday T. D., Yajnik C. S. Central rather than generalized obesity is related to hyperglycaemia in Asian Indian subjects. Diabet Med. 1991 Oct;8(8):712–717. doi: 10.1111/j.1464-5491.1991.tb01689.x. [DOI] [PubMed] [Google Scholar]
  126. Shepherd J., Betteridge D. J., Durrington P., Laker M., Lewis B., Mann J., Miller J. P., Reckless J. P., Thompson G. R. Strategies for reducing coronary heart disease and desirable limits for blood lipid concentrations: guidelines of the British Hyperlipidaemia Association. Br Med J (Clin Res Ed) 1987 Nov 14;295(6608):1245–1246. doi: 10.1136/bmj.295.6608.1245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  127. Shepherd J., Cobbe S. M., Ford I., Isles C. G., Lorimer A. R., MacFarlane P. W., McKillop J. H., Packard C. J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301–1307. doi: 10.1056/NEJM199511163332001. [DOI] [PubMed] [Google Scholar]
  128. Short C. D., Durrington P. N. Hyperlipidaemia and renal disease. Baillieres Clin Endocrinol Metab. 1990 Dec;4(4):777–806. doi: 10.1016/s0950-351x(05)80079-5. [DOI] [PubMed] [Google Scholar]
  129. Smith G. D., Song F., Sheldon T. A. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ. 1993 May 22;306(6889):1367–1373. doi: 10.1136/bmj.306.6889.1367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. Smith P., Arnesen H., Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med. 1990 Jul 19;323(3):147–152. doi: 10.1056/NEJM199007193230302. [DOI] [PubMed] [Google Scholar]
  131. Smith S. J., Markandu N. D., Sagnella G. A., MacGregor G. A. Moderate potassium chloride supplementation in essential hypertension: is it additive to moderate sodium restriction? Br Med J (Clin Res Ed) 1985 Jan 12;290(6462):110–113. doi: 10.1136/bmj.290.6462.110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  132. Staessen J. A., Fagard R., Thijs L., Celis H., Arabidze G. G., Birkenhäger W. H., Bulpitt C. J., de Leeuw P. W., Dollery C. T., Fletcher A. E. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997 Sep 13;350(9080):757–764. doi: 10.1016/s0140-6736(97)05381-6. [DOI] [PubMed] [Google Scholar]
  133. Stamler J., Neaton J. D., Wentworth D. N. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension. 1989 May;13(5 Suppl):I2–12. doi: 10.1161/01.hyp.13.5_suppl.i2. [DOI] [PubMed] [Google Scholar]
  134. Stamler R., Stamler J., Grimm R., Gosch F. C., Elmer P., Dyer A., Berman R., Fishman J., Van Heel N., Civinelli J. Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial--the Hypertension Control Program. JAMA. 1987 Mar 20;257(11):1484–1491. doi: 10.1001/jama.257.11.1484. [DOI] [PubMed] [Google Scholar]
  135. Swales J. D. Non-pharmacological antihypertensive therapy. Eur Heart J. 1988 May;9 (Suppl G):45–52. doi: 10.1093/eurheartj/9.suppl_g.45. [DOI] [PubMed] [Google Scholar]
  136. Thompson G. R. What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease? Atherosclerosis. 1997 May;131(1):1–5. doi: 10.1016/s0021-9150(97)06084-x. [DOI] [PubMed] [Google Scholar]
  137. Treating mild hypertension. Report of the British Hypertension Society working party. BMJ. 1989 Mar 18;298(6675):694–698. doi: 10.1136/bmj.298.6675.694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  138. Ul Haq I., Ramsay L. E., Pickin D. M., Yeo W. W., Jackson P. R., Payne J. N. Lipid-lowering for prevention of coronary heart disease: what policy now? Clin Sci (Lond) 1996 Oct;91(4):399–413. doi: 10.1042/cs0910399. [DOI] [PubMed] [Google Scholar]
  139. Watkins L. O., Neaton J. D., Kuller L. H. Racial differences in high-density lipoprotein cholesterol and coronary heart disease incidence in the usual-care group of the Multiple Risk Factor Intervention Trial. Am J Cardiol. 1986 Mar 1;57(8):538–545. doi: 10.1016/0002-9149(86)90831-3. [DOI] [PubMed] [Google Scholar]
  140. Wenting G. J., Derkx F. H., Tan-Tjiong L. H., van Seyen A. J., Man in't Veld A. J., Schalekamp M. A. Risks of angiotensin converting enzyme inhibition in renal artery stenosis. Kidney Int Suppl. 1987 May;20:S180–S183. [PubMed] [Google Scholar]
  141. Yusuf S., Collins R., Peto R. Why do we need some large, simple randomized trials? Stat Med. 1984 Oct-Dec;3(4):409–422. doi: 10.1002/sim.4780030421. [DOI] [PubMed] [Google Scholar]
  142. Zanchetti A. Goals of antihypertensive treatment: prevention of cardiovascular events and prevention of organ damage. Blood Press. 1992 Dec;1(4):205–211. doi: 10.3109/08037059209077664. [DOI] [PubMed] [Google Scholar]
  143. de Lorgeril M., Renaud S., Mamelle N., Salen P., Martin J. L., Monjaud I., Guidollet J., Touboul P., Delaye J. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1994 Jun 11;343(8911):1454–1459. doi: 10.1016/s0140-6736(94)92580-1. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES